Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study.

BACKGROUND: Intensive lipid-lowering therapy may induce coronary atherosclerosis regression. Nevertheless, the factors underlying the effect of lipid-lowering therapy on disease regression remain poorly characterized. Our aim was to determine which characteristics of atherosclerotic plaque are associated with a greater reduction in coronary plaque burden (PB) after treatment with alirocumab in patients with familial hypercholesterolemia. METHODS: The ARCHITECT study (Effect of Alirocumab on Atherosclerotic Plaque Volume, Architecture and Composition) is a phase IV, open-label, multicenter, single-arm clinical trial to assess the effect of the treatment with alirocumab for 78 weeks on the coronary atherosclerotic PB and its characteristics in subjects with familial hypercholesterolemia without clinical atherosclerotic cardiovascular disease. Participants underwent a coronary computed tomographic angiography at baseline and a final one at 78 weeks. Every patient received alirocumab 150 mg subcutaneously every 14 days in addition to high-intensity statin therapy. RESULTS: One hundred and four patients were enrolled. Median age was 53.3 (46.2-59.4) years and 54 were women (51.9%). The global coronary PB changed from 34.6% (32.5%-36.8%) at entry to 30.4% (27.4%-33.4%) at follow-up, which is -4.6% (-7.7% to -1.9%; P<0.001) reduction. A decrease in the percentage of unstable core (fibro-fatty+necrotic plaque; from 14.1 [7.9-22.3] to 8.0 [6.4-10.6]; -6.6%; P<0.001) was found. A greater PB (ß, 0.36 [0.13-0.59]; P=0.002) and a higher proportion of unstable core (ß, 0.15 [0.08-0.22]; P<0.001) were significantly related to PB regression. CONCLUSIONS: Treatment with alirocumab in addition to high-intensity statin therapy might produce a greater PB regression in patients with familial hypercholesterolemia with higher baseline PB and in those with larger unstable core. Further studies are needed to corroborate the hypothesis raised by these results. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05465278.

Hiperparatiroidismo primario: una forma infrecuente de presentación / Primary hyperparathyroidism: an unusual presentation

No disponible

Cetoacidosis diabética asociada a tratamiento con canagliflozina / Canagliflozin induced diabetic ketoacidosis

No disponible

Nutrición de yodo en mujeres embarazadas del área de Oviedo. ¿Es necesaria la suplementación con yodo? / Iodine nutrition in pregnant women from Oviedo area. Is iodine supplementation necessary?

INTRODUCCIÓN Y OBJETIVO: En Asturias, donde la deficiencia de yodo fue erradicada en los escolares en el año 2000, persistía una deficiencia de yodo en las mujeres embarazadas, por lo que se les recomendaba la utilización de suplementos yodados. El objetivo de este estudio es conocer la nutrición de yodo de las mujeres embarazadas de nuestra área y la necesidad o no de suplementos yodados. MATERIAL Y MÉTODOS: Durante mayo y junio de 2013 hemos estudiado la nutrición de yodo y la función tiroidea en el primer trimestre del embarazo de 173 mujeres del área sanitaria de Oviedo. RESULTADOS: La mediana de la yoduria fue 197 μg/L. Tomaban suplementos yodados el 47% de las mujeres, con una mediana de yoduria superior a la de las que no tomaban suplementos yodados (247 vs 138 μg/L; <0,001) y también una TSH superior (2,30 vs 1,94 mU/L), aunque no significativamente diferente. La yoduria fue también superior en las mujeres que tomaban más de 2 raciones de productos lácteos (mediana: 230 μg/L) que en aquellas que tomaban menos de 2 raciones (mediana: 191 μg/L). Dentro del grupo de mujeres que no tomaban suplementos yodados, aquellas que utilizaban habitualmente sal yodada en la cocina (47%), tenían una mediana de yoduria de 190 μg/L, indicativa de suficiencia de yodo. CONCLUSIÓN: En la actualidad los suplementos yodados serían innecesarios en las mujeres embarazadas de nuestra entorno que consumen de forma habitual sal yodada y la recomendación en estos casos debería ser la de continuar utilizando la sal yodada en la cantidad recomendada en la gestación, así como consumir al menos dos raciones diarias de leche o productos lácteos

BACKGROUND AND OBJECTIVE: In Asturias, where iodine deficiency was eradicated in school children by the year 2000, iodine deficiency persisted in pregnant women, who were recommended to use of iodine supplementation. The aim of this study was to determine the iodine nutrition of pregnant women in our area and whether or not iodine supplements are needed. MATERIAL AND METHODS: Throughout May and June 2013 we studied the iodine nutrition and thyroid function during the first trimester of pregnancy in 173 women in the health area of Oviedo. RESULTS: The median urinary iodine was 197 μg/L. Iodinated supplements were used by 47% of women, which had a yoduria median higher than those not taking iodinated supplements (247 vs. 138 μg/L; p < .001), and also a higher TSH (2.30 vs 1.94 mU/L) although not significantly different. Yoduria was also higher in women who took more than 2 servings of dairy products (median: 230 μg/L) than those who took less (median: 191 μg/L). Within the group of women who were not taking iodine supplements, those regularly using iodized salt in the kitchen (47%) had a median urinary iodine concentration of 190 μg/L indicating iodine sufficiency. CONCLUSIONS: Iodinated supplements seem unnecessary nowadays in pregnant women of Oviedo who regularly take iodized salt and our recommendation in these cases should be to continue the use of iodized salt in the recommended amounts during pregnancy and consume at least two daily servings of milk or dairy products